Results 151 to 160 of about 241,371 (303)

Release of Anticancer Drug Doxorubicin from Biodegradable Polymer Coated Porous Hydroxyapatite Scaffolds

open access: yes
In the current research slow release anticancer drug delivery system was prepared and drug release kinetics in vitro evaluated. Porous hydroxyapatite (HAp) as carrier material and doxorubicin hydrochloride (DOX) as anticancer agent was used.
Pelšs, Juris   +4 more
core  

Fibrotic Rewiring of CD8<sup>+</sup> T Cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix. [PDF]

open access: yesJACC CardioOncol
Bayer AL   +10 more
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy

open access: yes, 2017
Wei Jiang Goh,1,2 Choon Keong Lee,2 Shui Zou,2 Esther CY Woon,2 Bertrand Czarny,2,3 Giorgia Pastorin1,2,4 1NUS Graduate School for Integrative Sciences and Engineering, Centre for Life Sciences (CeLS), 2Department of Pharmacy, National University of ...
Lee CK   +5 more
core  

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng   +7 more
wiley   +1 more source

Cardiac and Mitochondrial Adaptations in Response to Aging and Doxorubicin in Rats Bred for Divergent Aerobic Capacities

open access: yes, 2012
Doxorubicin (DOX) remains as one of the most widely prescribed and effective anticancer agents. A major limitation of the therapeutic effectiveness of the drug is the occurrence of irreversible progressive dose-dependent cardiotoxicity.
Larion, Laura   +1 more
core  

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy